{"organizations": [], "uuid": "dc55e2beb6a4804a0c365c29465a4561d36ca2b6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/UKHealth", "section_title": "Reuters: Health News", "url": "https://uk.reuters.com/article/us-amgen-fda-xgeva/fda-expands-use-of-amgens-blockbuster-drug-idUKKBN1EU1J1", "country": "US", "domain_rank": 408, "title": "FDA expands use of Amgen's blockbuster drug", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-05T17:22:00.000+02:00", "replies_count": 0, "uuid": "dc55e2beb6a4804a0c365c29465a4561d36ca2b6"}, "author": "", "url": "https://uk.reuters.com/article/us-amgen-fda-xgeva/fda-expands-use-of-amgens-blockbuster-drug-idUKKBN1EU1J1", "ord_in_thread": 0, "title": "FDA expands use of Amgen's blockbuster drug", "locations": [], "entities": {"persons": [{"name": "akankshita mukhopadhyay", "sentiment": "none"}, {"name": "xgeva", "sentiment": "none"}], "locations": [{"name": "south america", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}, {"name": "asia", "sentiment": "none"}, {"name": "europe", "sentiment": "none"}, {"name": "xgeva", "sentiment": "none"}, {"name": "australia", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "amgen", "sentiment": "negative"}, {"name": "glaxosmithkline", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "amgen inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 5, 2018 / 3:24 PM / Updated 23 minutes ago FDA expands use of Amgen's blockbuster drug Reuters Staff 1 Min Read \n(Reuters) - Amgen Inc said on Friday that the U.S. Food and Drug Administration approved its drug, Xgeva, to prevent fractures in patients with multiple myeloma. FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Photo \nXgeva has already been approved to treat a condition in which the calcium level in blood is above normal and giant cell tumor of the bone. \nAmgen reacquired sales rights to Xgeva along with two other drugs from British drugmaker GlaxoSmithKline in 2015.( reut.rs/2F43mf5 ) \nThe deal gave the drugmaker rights to sell in 48 countries, including Australia as well as markets in Asia, South America and Europe. \nXgeva is one of Amgenâ€™s key growth drivers and had raked in $1.53 billion in sales in 2016. Reporting by Akankshita Mukhopadhyay in Bengaluru", "external_links": [], "published": "2018-01-05T17:22:00.000+02:00", "crawled": "2018-01-05T17:56:57.013+02:00", "highlightTitle": ""}